Inactive Instrument

Highlights Novartis AG Swiss Exchange

Equities

CH0012005267

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

06-07	Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	MT
06-07	Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	06-07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	06-07	MT
Novartis and others face Italy antitrust probe over eye drug	06-06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	06-05	DJ
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	05-31	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	05-31	MT
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	05-31	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	05-31	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	05-31	MT
Novartis: positive trial results in chronic myeloid leukemia	05-31	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	05-31	MT
Novartis Presents Positive Results from the Pivotal Phase III ASC4FIRST Trial	05-31	CI
Novartis: efficacy of remibrutinib in urticaria -USC	05-31	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	05-31	MT
Novartis Phase III Data Confirms Sustained Efficacy and Long-Term Safety of Oral Remibrutinib in Chronic Spontaneous Urticaria	05-30	CI
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	05-30	DJ
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	05-30	MT
Novartis: positive phase III results in C3G	05-27	CF